All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

EMA recommends Kygevvi for rare thymidine kinase 2 deficiency, marking first authorized treatment for condition
Small molecule, rare disease, regulatory, orphan drug - Read more

THE GOOD
Business Development & Partnerships

Kahimmune Therapeutics, Gustave Roussy, SATT Paris-Saclay license exclusive dark genome neoantigens platform for mRNA cancer vaccines
Licensing deal, oncology, vaccine, mRNA therapy - Read more

Cellares, Stanford Center for Definitive and Curative Medicine collaborate on automated gene-edited stem cell manufacturing
Research collaboration, gene therapy, manufacturing, rare disease - Read more

Insilico Medicine receives $5M milestone from Menarini Group for MEN2501 first-in-human dosing achievement
Licensing deal, oncology, AI/ML, small molecule, milestone payments - Read more

Zonsen PepLib Biotech, Eli Lilly collaborate on peptide-based drug candidates with upfront payments and milestone eligibility
Research collaboration, drug discovery, milestone payments, royalties - Read more

HOOKIPA Pharma sells oncology assets HB-200, HB-700 to NeoTrail Therapeutics, undisclosed purchase price
Asset sale, oncology, gene therapy, R&D - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Clinical Trials

Pfizer's PF-08653944 demonstrates 12.3% weight loss in Ph2 trial for obesity with monthly GLP-1 receptor agonist dosing
Protein therapy, metabolic, GLP-1 receptor agonist, obesity, monthly dosing - Read more

Persica Pharmaceuticals' PP353 shows positive Ph1b results for chronic low back pain with Modic changes
Small molecule, pain management, intradiscal injection, chronic low back pain, bacterial infection target - Read more

Ultragenyx Pharmaceutical's UX111 (rebisufligene etisparvovec) shows sustained biomarker improvements in Sanfilippo syndrome gene therapy study
Gene therapy, neurological, AAV gene therapy, Sanfilippo syndrome, lysosomal storage disorder - Read more

THE GOOD
Earnings & Finances

Merck & Co. projects $70B+ annual revenue opportunities by mid-2030s, preparing for post-Keytruda future with expanded pipeline
Monoclonal antibody, oncology, strategic, major transaction - Read more

Merck & Co. defends growth strategy amid analyst criticism, highlights $19B acquisitions and broad pipeline expansion
Vaccine, oncology, strategic, major transaction - Read more

THE GOOD
Fundraises

HemostOD awarded $2.5M Innosuisse grant for donor-free universal platelet development
Cell therapy, platform technology, manufacturing, preclinical - Read more

Phylo raises $13.5M seed funding for biomedical AI agents and drug discovery
AI/ML platform, drug discovery, biomedical research, platform technology - Read more

Veradermics prices upsized $256M IPO, dermatological and aesthetic therapeutics development
Dermatology, clinical-stage, aesthetic therapeutics - Read more

AccurEdit Therapeutics raises $75M Series A to advance CRISPR gene editing pipeline
CRISPR, gene therapy, cardiovascular, in vivo gene editing, clinical-stage - Read more

Exxel Pharma plans $13M IPO for FAAH inhibitor chronic cough trials
Small molecule, pain management, neurological, FAAH inhibitor, clinical-stage - Read more

THE GOOD
Investments

India invests $1.1B in SHAKTI initiative to boost biologics and biosimilars development over five years
Biologics, oncology, strategic, major transaction - Read more

THE GOOD
Politics & Policy

NIH Director Bhattacharya acknowledges no vaccine-autism link amid Senate hearing on agency modernization efforts
Vaccine, infectious disease, regulatory, operational - Read more

THE GOOD
Product Launches

IBSA UK&I launches Perovial, first licensed hyaluronic acid injectable treatment for acute Peyronie's disease
Hyaluronic acid injectable, rare disease, strategic, operational - Read more

THE GOOD
Regulatory

HHS launches $100M SMART Prize competition to develop broad-spectrum antiviral therapies for dengue, zika viruses
Small molecule, infectious disease, major transaction, strategic - Read more

FDA announces flexible regulatory approach to shepherd CAR-T therapies for autoimmune diseases development
CAR-T, autoimmune, regulatory, strategic - Read more

FDA grants priority review to AstraZeneca's Datroway for metastatic triple-negative breast cancer treatment
Antibody-drug conjugate, oncology, regulatory, strategic - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Approvals & Labels

FDA rejects AstraZeneca's subcutaneous Saphnelo (anifrolumab) prefilled pen for systemic lupus erythematosus treatment
Antibody, autoimmune, monoclonal antibody, lupus, subcutaneous formulation - Read more

THE BAD
Clinical Trials

NMD Pharma's ignaseclant misses primary endpoint in Ph2a Charcot-Marie-Tooth disease trial despite secondary improvements
Small molecule, neurological, ion channel inhibitor, Charcot-Marie-Tooth disease, neuromuscular disorder - Read more

THE BAD
Earnings & Finances

Pfizer posts fourth-quarter revenue beat but takes $4.4B write-down on R&D projects
Antibody-drug conjugate, oncology, financial, major transaction, strategic - Read more

Novo Nordisk shares drop 14% after predicting 5% sales decline for 2026 amid U.S. pricing pressures
GLP-1 agonist, metabolic disease, financial, revenue impact - Read more

THE BAD
Layoffs

Charles River Laboratories closes Maryland cell therapy CDMO site, laying off 20 employees amid restructuring
Cell therapy, operational, strategic, cost reduction - Read more

THE BAD
Regulatory

Sanofi sanctioned by PMCPA over CEO's disparaging claims about Pfizer's RSV vaccine Abrysvo procurement choice
Vaccine, infectious disease, regulatory, competitive - Read more

THE BAD
Strategic Plans

Daiichi Sankyo ends in-house development of DS-9606 ADC following strategic portfolio review
Antibody-drug conjugate, oncology, strategic, operational - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here